FDA approval in 30 days: Congress fast-tracks foreign drug approvals

What it does

This bill creates a fast-track approval pathway for drugs and biologics already approved by trusted foreign regulators (EU, UK, Canada, and others designated by HHS) to be sold in the US without full FDA review. A company can request 'reciprocal approval' by submitting the foreign regulator's dossier; the FDA has 30 days to approve or deny. The bill also allows clinical trials authorized abroad to proceed in the US under the same 30-day timeline. Both pathways apply only to drugs for immediately life-threatening diseases. The FDA retains authority to withdraw approval if new safety data emerges or the foreign regulator withdraws its own approval.

Why we flagged it

The bill's core mechanism is a reciprocal approval shortcut that bypasses traditional FDA review in favor of relying on foreign regulatory authorization. While framed as patient access acceleration, the operative effect is a material reduction in pre-market FDA scrutiny for a defined class of drugs.

What the text implies

• The 30-day approval window is extremely tight for FDA to conduct any independent safety analysis; in practice, approval becomes nearly automatic if the foreign regulator's dossier is submitted, shifting the burden of safety assurance to foreign agencies whose standards may differ from US norms.
• The bill does not require the FDA to verify that foreign regulatory processes are equivalent to US standards; it merely designates certain authorities as 'trusted' without defining what makes them trustworthy or establishing ongoing equivalence review.

The full analysis lists 5 implications of this text.

Who stands to gain

pharmaceutical companies and biologics manufacturers; companies with drugs approved in EU/UK/Canada seeking US market entry